Abstract:The zinc-containing histone deacetylase enzyme HDAC7 is emerging as an important regulator of immunometabolism and cancer. Here, we exploit a cavity in HDAC7, filled by Tyr303 in HDAC1, to derive new inhibitors. Phenacetyl hydroxamates and 2-phenylbenzoyl hydroxamates bind to Zn2+ and are 50–2700-fold more selective inhibitors of HDAC7 than HDAC1. Phenylbenzoyl hydroxamates are 30–70-fold more potent HDAC7 inhibitors than phenacetyl hydroxamates, which is attributed to the benzoyl aromatic group interacting with Phe679 and Phe738. Phthalimide capping groups, including a saccharin analogue, decrease rotational freedom and provide hydrogen bond acceptor carbonyl/sulfonamide oxygens that increase inhibitor potency, liver microsome stability, solubility, and cell activity. Despite being the most potent HDAC7 inhibitors to date, they are not selective among class IIa enzymes. These strategies may help to produce tools for interrogating HDAC7 biology related to its catalytic site.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01967?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01967</a>.Additional experimental procedures, figures and tables describing modelling for alternative docked ligand poses in HDAC7, chemical synthesis, and compound characterization (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_001.pdf">PDF</a>)Figure 3 docking pose for compound 5a (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_002.pdb">PDB</a>)Figure 4 docking pose for compound 5a (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_003.pdb">PDB</a>)Figure 4 docking pose for compound 22 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_004.pdb">PDB</a>)Figure 4 docking pose for compound 31 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_005.pdb">PDB</a>)Figure S1 docking pose for compound 5a (without water) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_006.pdb">PDB</a>)Figure S1 docking pose for compound 5a (with water) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_007.pdb">PDB</a>)Figure S2 docking pose for compound 15 (with water) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_008.pdb">PDB</a>)Figure S3 docking pose for compound 22 (with water) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_009.pdb">PDB</a>)Figure S3 docking pose for compound 30 (with water) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_010.pdb">PDB</a>)Figure S3 docking pose for compound 31 (with water) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_011.pdb">PDB</a>)SMILES strings of all compounds used for docking (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_012.csv">CSV</a>)This article has not yet been cited by other publications.

Inhibition And Mechanism Of Hdac8 Revisited

Computational Exploration of Zinc Binding Groups for Hdac Inhibition

HDAC8 as a target in drug discovery: Function, structure and design

Crucial Structural Understanding for Selective HDAC8 Inhibition: Common Pharmacophores, Molecular Docking, Molecular Dynamics, and Zinc Binder Analysis of selective HDAC8 inhibitors

Structure-Function Analysis of the Conserved Tyrosine and Diverse Π-Stacking among Class I Histone Deacetylases: A QM (DFT)/MM MD Study

Unveiling critical structural features for effective HDAC8 inhibition: a comprehensive study using quantitative read-across structure–activity relationship (q-RASAR) and pharmacophore modeling

HDAC7 Inhibition by Phenacetyl and Phenylbenzoyl Hydroxamates

Discussion on structure classification and regulation function of histone deacetylase and their inhibitor

Homology modeling and in silico design of novel and potential dual-acting inhibitors of human histone deacetylases HDAC5 and HDAC9 isozymes

Identification of Ligand Features Essential for HDACs Inhibitors by Pharmacophore Modeling.

The pivotal role of histidine 976 in human histone deacetylase 4 for enzyme function and ligand recognition

Quantitative Structure-Activity Relationship Study of Histone Deacetylase Inhibitors.

Competitive or noncompetitive, that's the question: research toward histone deacetylase inhibitors

Exploring Inhibitor Release Pathways in Histone Deacetylases Using Random Acceleration Molecular Dynamics Simulations

Discovery of Histone Deacetylase 8 Selective Inhibitors

Activity-Guided Design of HDAC11-Specific Inhibitors.

The Development Process: from SAHA to Hydroxamate HDAC Inhibitors with Branched CAP Region and Linear Linker

Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors

Exploring different classification-dependent QSAR modelling strategies for HDAC3 inhibitors in search of meaningful structural contributors

Chemical Versatility in Catalysis and Inhibition of the Class IIb Histone Deacetylases

Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases